the aid library

Consensus Document for Management of Larynx and Hypopharynx Cancers

Indian Council of Medical Research (ICMR) (2017) C1

Prepared as an outcome of ICMR Subcommittee on Larynx & Hypopharynx Cancers | This consensus document on management of larynx and hypopharynx cancers summarizes the modalities of treatment including the site-specific anti- ... more

A Textbook of Gynecology for Less-Resourced Locations

Heleen van Beekhuizen and Regine Unkels The Global Library of Women’s Medicine by Sapiens Publishing (2012)

This textbook seeks to support various levels of health personnel in less-resourced locations by providing evidence-based information about low-tech diagnostic and treatment options for common gynecological conditions such as cervical, ovarian and b ... more

Q&A: Antibiotic resistance: where does it come from and what can we do about it?

Wright G.D. BMC Biology (2010) C2

Historically, the discovery of the sulfa drugs in the 1930s and the subsequent development of penicillin during World War II ushered in a new era in the treatment of infectious diseases. Infections that ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature

Ocran Mattila, P.; R. Ahmad, S.Shahzad Hasan, et al. (2021) C2

Front. Public Health, 30 April 2021 | https://doi.org/10.3389/fpubh.2021.628744

International Cancer Control Partnership Portal
recommended

International Cancer Control Partnership (2022) CC

the one-stop shop online resource for cancer planners. Here you can find a library of resouces for develop a national cancre control plan, statistics, stay updated, technical assistance and you can discover on an interactive map ... more

Guide to cancer early diagnosis
recommended

World Health Organization WHO (2017) C_WHO

Enfermedades no transmisibles - Las enfermedades crónicas, no transmisibles (ENT) son la principal causa de muerte y discapacidad en el mundo

Pan American Health Organization PAHO (2024) C_WHO

Chronic noncommunicable diseases (NCDs) are the number one cause of death and disability in the world. The term NCDs refers to a group of conditions that are not mainly caused by an acute infection, result in long-term health consequences and often create a need for long-term ... more

Progress on the prevention and control of non-communicable diseases : report of the Secretary-General - chinese version

United Nations Secretary-General United Nations General Assembly (2017) C_WHO

The document, "Progress on the Prevention and Control of Non-Communicable Diseases," reports on global efforts to reduce the impact of NCDs, such as heart disease, cancer, diabetes, and chronic respiratory diseases, following the commitments made at ... more

Cancer of the cervix

Hesperian (2021) CC

A Book for Midwives > Chapter 20: The Pelvic Exam: how to examine a woman's vagina and womb > Cancer of the cervix

Kenya: National Cancer Control Strategy 2017-2022

Ministry of Health, Kenya (2017) C1

Policy statement and recommended actions for early detection of cervical cancer in the Eastern Mediterranean Region

World Health Organization WHO; Eastern Mediterranean Region (2022) C_WHO

Policy Statement